CompletedPhase 2NCT00106184
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pittsburgh
- Principal Investigator
- Chester V. Oddis, MDUniversity of Pittsburgh
- Intervention
- Rituximab(drug)
- Enrollment
- 200 enrolled
- Eligibility
- 5 years · All sexes
- Timeline
- 2006 – 2010
Study locations (30)
- University of Alabama Arthritis Intervention Program (Adult Site), Birmingham, Alabama, United States
- Phoenix Neurological Associates, LTD (Adult Site), Phoenix, Arizona, United States
- Cedars-Sinai Medical Center (Adult Site), Los Angeles, California, United States
- Stanford University (Adult Site), Stanford, California, United States
- Stanford University (Pediatric Site), Stanford, California, United States
- University of Miami School of Medicine (Adult Site), Miami, Florida, United States
- Miami Children's Hospital (Pediatric Site), Miami, Florida, United States
- University of Kansas Medical Center (Adult Site), Kansas City, Kansas, United States
- Kentucky Clinic (Adult Site), Lexington, Kentucky, United States
- National Institute of Health (Adult Site), Bethesda, Maryland, United States
- National Institute of Health (Pediatric Site), Bethesda, Maryland, United States
- Children's Hospital of Boston (Pediatric Site), Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center (Adult Site), Boston, Massachusetts, United States
- University of Michigan Health System (Adult Site), Ann Arbor, Michigan, United States
- Michigan State University (Adult and Pediatric Site), Grand Rapids, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Genentech, Inc. · Biogen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00106184 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH